Welcome to our dedicated page for Can-Fite BioPharma Ltd. SEC filings (Ticker: CANF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Can-Fite BioPharma Ltd. filings document foreign-private-issuer disclosures for a clinical-stage biotechnology company whose American Depositary Shares trade under CANF. Its Form 6-K reports furnish press releases, annual and special meeting materials, proxy statements, voting instruction cards for ADS holders, and shareholder-vote results.
The company’s regulatory record covers clinical and regulatory updates for A3AR drug candidates, Namodenoson and Piclidenoson patent matters, partner-related development disclosures, operating and financial results, capital-structure items, registration-statement incorporation for Form S-8 and Form F-3 filings, governance matters, and risks connected to drug development and public-company financing.
Can-Fite BioPharma Ltd., an Israel-based foreign private issuer, submitted a Form 6-K to furnish a new press release and update its existing registration statements. The company reports that it issued a press release on September 15, 2025 titled “Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson,” describing a clinical outcome in a decompensated cirrhosis patient treated with its drug candidate Namodenoson.
The first paragraph of this press release is incorporated by reference into Can-Fite’s effective Form S-8 and Form F-3 registration statements, meaning the information in that paragraph is now formally part of those securities offering documents. The press release itself is attached to this report as Exhibit 99.1.
Can-Fite BioPharma Ltd., an Israel-based foreign private issuer, submitted a Form 6-K to furnish a new press release and update its existing registration statements. The company reports that it issued a press release on September 15, 2025 titled “Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson,” describing a clinical outcome in a decompensated cirrhosis patient treated with its drug candidate Namodenoson.
The first paragraph of this press release is incorporated by reference into Can-Fite’s effective Form S-8 and Form F-3 registration statements, meaning the information in that paragraph is now formally part of those securities offering documents. The press release itself is attached to this report as Exhibit 99.1.
Can-Fite BioPharma Ltd. filed a Form 6-K as a foreign private issuer to provide investors with its operating and financial review and unaudited interim condensed consolidated financial statements for the six months ended June 30, 2025. The company also issued a press release on that date summarizing its financial results for the period and giving updates on its drug development programs. The 6-K specifies that the financial review, interim financial statements, and portions of the press release are incorporated by reference into several existing Form S-8 and Form F-3 registration statements, allowing those registration statements to use the newly furnished information.
Can-Fite BioPharma (CANF) has filed a Rule 424(b)(4) prospectus for a best-efforts capital raise. The company will sell up to 1.25 million American Depositary Shares (ADSs) at $0.60 each (1 ADS=300 ordinary shares) bundled with 2.5 million two-year Common Warrants exercisable at $0.60. Investors that would exceed 4.99%/9.99% ownership can instead buy up to 7.083 million Pre-Funded Warrants at $0.599, each exercisable for one ADS at $0.001. The filing also registers 583,333 Placement Agent Warrants (exercise price $0.75) and up to 24.33 million ADSs issuable upon warrant exercise.
Gross proceeds could reach $4.99 million; after 7% placement fee, 1% management fee and ~$246k expenses, net proceeds are estimated at $4.19 million. Funds will support R&D, clinical trials and general corporate purposes at management’s discretion.
Capital impact: outstanding ordinary shares rise from 3.997 billion (13.323 million ADSs) to 4.372 billion (14.573 million ADSs), a ~9% increase, or ~63% if all Pre-Funded Warrants are exercised immediately (total 8.333 million new ADSs). The warrants’ two-year term and low exercise price cap potential upside for existing holders and add future dilution.
CANF’s ADSs closed at $1.02 on 22 Jul 2025, a 70% premium to the $0.60 offer price, suggesting short-term pricing pressure. The deal includes 90-day lock-ups for the company and insiders and a one-year prohibition on variable-rate financings (subject to waiver).
Can-Fite BioPharma (CANF) disclosed a $5.0 million best-efforts public offering of equity and warrants. The July 28, 2025 deal comprises (i) 1.25 million ADSs (each equal to 300 ordinary shares) and (ii) 7.08 million pre-funded warrants plus 16.67 million common warrants, all priced at a combined $0.60 per ADS/ warrant unit ($0.599 for pre-funded units). Net proceeds after fees are expected to be $4.19 million.
The pre-funded warrants are immediately exercisable at $0.001 per ADS with no expiry; common warrants carry a $0.60 strike and two-year tenor. Exercisability is capped at 4.99% (optionally 9.99%) beneficial ownership. A single investor executed a definitive Securities Purchase Agreement that imposes a 90-day standstill and prohibits “variable-rate” financings for one year.
H.C. Wainwright acted as exclusive placement agent, earning 7% cash commission, 1% management fee, fixed expenses (~$165k) and agent warrants covering 7% of ADSs/pre-funded warrants, exercisable at $0.75.
Funds will support additional working capital, R&D and clinical trials. The offering, registered on Form F-1 (File No. 333-288890) declared effective July 28 2025, is expected to close on or about July 29 2025, subject to customary conditions.
On 28 Jul 2025, Can-Fite BioPharma Ltd. (CANF) furnished a Form 6-K to the SEC. The sole substantive disclosure is that a press release titled “Breakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment for Vascular Dementia” is attached as Exhibit 99.1. The filing does not include financial figures, guidance or trial details, but the headline signals an expansion opportunity for Piclidenoson into the large, underserved vascular dementia market. If future data confirm efficacy, this new indication could materially broaden the drug’s commercial potential and strengthen CANF’s pipeline value.
No information is given on study size, statistical significance, regulatory path or timelines. Investors will need the full Exhibit 99.1 or follow-up communications to assess clinical strength, competitive positioning and potential revenue impact.
On 28 Jul 2025, Can-Fite BioPharma Ltd. (CANF) furnished a Form 6-K to the SEC. The sole substantive disclosure is that a press release titled “Breakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment for Vascular Dementia” is attached as Exhibit 99.1. The filing does not include financial figures, guidance or trial details, but the headline signals an expansion opportunity for Piclidenoson into the large, underserved vascular dementia market. If future data confirm efficacy, this new indication could materially broaden the drug’s commercial potential and strengthen CANF’s pipeline value.
No information is given on study size, statistical significance, regulatory path or timelines. Investors will need the full Exhibit 99.1 or follow-up communications to assess clinical strength, competitive positioning and potential revenue impact.
Can-Fite BioPharma announced the adjournment of its Annual General Meeting of Shareholders originally scheduled for June 23, 2025, due to lack of quorum. The meeting has been rescheduled for June 30, 2025, at 3:00 p.m. Israel time and will be held at the company's offices in Ramat Gan, Israel.
The Form 6-K was signed by Motti Farbstein, who serves as both Chief Executive Officer and Chief Financial Officer of the company. This regulatory filing fulfills the company's obligation to report material events to shareholders under Securities Exchange Act requirements.